Recent progress in the pharmacotherapy of Churg-Strauss syndrome

Bibliography

• CHURG JSL: Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am. Pathol. (1951) 27:272–301.
   Google Scholar
• GROSS W: Churg-Strauss syndrome: update on recent developments. Carr: Opin. Rheumatol. (2002) 14:11–14.
   PubMed Web of Science ®Google Scholar
• CHUMBLEY LC, HARRISON EG Jr, DEREMEE RA: Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin. Proc. (1977) 52:477–484.
   PubMed Web of Science ®Google Scholar
• LANHAM J, ELKON K, PUSEY C, HUGHES G: Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (1984) 63:65–81.
   PubMed Web of Science ®Google Scholar
• NOTH I, STREK M, LEFF A: Churg-Strauss syndrome. Lancet (2003) 361:587–594.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA T, CAO B, TAKEUCHI N et al.: Clinicopathological studies of peripheral neuropathy in Churg-Strauss syndrome. Neuropathology (2002) 22:299–307.
   PubMedGoogle Scholar
• GUILLEVIN L, COHEN P, GAYRAUD M et al.: Churg-Strauss syndrome. Clinical study and long-term follow-up of 9 6 patients. Medicine (1999) 78:26–37.
   Google Scholar
• SOLANS R, BOSCH JA, PEREZ-BOCANEGRA C et al: Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (2001) 40:763–771.
   PubMed Web of Science ®Google Scholar
• LILLY C, CHURG A, LAZAROVICH M et al.: Asthma therapies and Churg-Strauss syndrome. I Allergy Clin. Immunol. (2002) 109:S1–S20.
   Google Scholar
• CONRON M, BEYNON H: Churg-Strauss syndrome. Thorax (2000) 55:870–877.
   PubMed Web of Science ®Google Scholar
• POTTER M, FINCHER R, FINGER D: Eosinophilia in Wegener's granulomatosis. Chest (1999) 116:1480–1483.
   PubMed Web of Science ®Google Scholar
• GROSS W, SCHMITT W, CSERNOK E: ANCA and associated diseases. immunodiagnostic and pathogenetic aspects. Clin. Exp. Immunol. (2001) 91:1–2.
   Google Scholar
• HOFFMAN GS: Classification of the systemic vasculitides. Clin. Exp. Rheumatol. (1998) 16:111–115.
   PubMedGoogle Scholar
• GROSS WL, SCHNABEL A, TRABANDT A: New perspectives in pulmonary angiitis. From pulmonary angiitis and granulomatosis to ANCA associated vasculitis. Sarcoidosis Vasc. Diffuse Lung Dis. (2000) 17:33–52.
   Google Scholar
• GUILLEVIN L, VISSER H, NOEL LH et al.: Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome - 62 patients. Rheumatol. (1993) 20:1345–1349.
   Google Scholar
• KALLENBERG CG, MULDER AH, TERVAERT JW: Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Am. Med. (1992) 93:675–682.
   PubMed Web of Science ®Google Scholar
• HOFFMAN GS, SPECKS U: Antineutrophil cytoplasmic antibodies. Arthritic Rheum. (1998) 41:1521–1537.
   PubMed Web of Science ®Google Scholar
• EUSTACE J, NADASDY T, CHOI M: The Churg-Strauss syndrome. I Am. Soc. Nephrol. (1999) 10:2048–2055.
   PubMedGoogle Scholar
• ARBACH 0, CSERNOK E, GROSS W, GAUSE A: Is the Churg-Strauss Syndrome an ANCA-associated vasculitis? Cleveland Clin.j Med. (2002) 69:173–174.
   Google Scholar
• HELLMICH B, CSERNOK E, GROSS W: 20 years with ANCA (antineutrophil cytoplasmic antibodies): from seromarker to major pathogenic player in vasculitis. Leukoc. Biol. (2003) 74:1–2.
   PubMed Web of Science ®Google Scholar
• MASI AT, HUNDER GG, LIE JT et al: The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritic Rheum. (1990) 33:1094–1100.
   PubMed Web of Science ®Google Scholar
• JENNETTE J, ANDRASSY K, BACON PAet al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritic Rheum. (1994) 37:187–192.
   PubMed Web of Science ®Google Scholar
• LANE SE, WATTS RA, BARKER TH, SCOTT DG: Evaluation of the Sorensen diagnostic criteria in the classification of systemic vasculitis. Rheumatology (2002) 41:1138–1141.
   PubMed Web of Science ®Google Scholar
• LEAVITT R, FAUCI A, BLOCH D et al:The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritic Rheum. (1990) 33:1101–1107.
   PubMed Web of Science ®Google Scholar
• RAO J, ALLEN N, PINCUS N: Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann. Intern. Med. (1998) 129:345–352.
   PubMed Web of Science ®Google Scholar
• SORENSEN SF, SLOT 0, TVEDE N, PETERSEN J: A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann. Rheum. Dis. (2000) 59:478–482.
   PubMedGoogle Scholar
• CHURG A, BRALLAS M, CRONIN S, CHURG J: Formes frustes of Churg-Strauss Syndrome. Chest (1995) 108:320–323.
   PubMedGoogle Scholar
• •The first report of four cases of CSS which developed after the cessation or dose reduction of corticosteroid treatment.
   Google Scholar
• REINHOLD-KELLER E, ZEIDLER A, GUTFLEISCH J et al: Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (2000) 39:1396–1402.
   PubMed Web of Science ®Google Scholar
• WATTS R, CARRUTHERS D, SCOTT D: Epidemiology of systemic vasculitis: Changing incidence or definition. Semin. Arthritis Rheum. (1995) 25:28–34.
   PubMed Web of Science ®Google Scholar
• REINHOLD-KELLER E, HERLYN K, WAGNER-BASTMEYER R et al: No difference in the incidences of vasculitides between north and south Germany: first results of the german vasculitis register. Rheumatology (2002) 41:540–549.
   PubMed Web of Science ®Google Scholar
• LOUGHLIN J, COLE J, ROTHMAN K,JOHNSON E: Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann. Allergy Asthma Immunol. (2002) 88:319–325.
   PubMed Web of Science ®Google Scholar
• HELLMICH B, EHLERS S, CSERNOK E, GROSS W: Update on the pathogenesis of Churg-Strauss syndrome. Clin. Exp. Rheumatol. (2003) (In Press).
   Google Scholar
• MUSCHEN M, WARSKULAT U, PERNIOK A et al.: Involvement of soluble CD95 in Churg-Strauss syndrome. Am. Pathol. (1999) 155:915–925.
   PubMed Web of Science ®Google Scholar
• SCHONERMARCK U, CSERNOK E, TRABANDT A, HANSEN H, GROSS WL: Circulating cytokines and soluble CD 23, CD26 and CD30 in ANCA- associated vasculitides [In Process Citation]. Clin. Exp. Rheumatol. (2000) 18:457–463.
   PubMed Web of Science ®Google Scholar
• KIENE M, CSERNOK E, MULLER A et al.: Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritic Rheum. (2001) 44:469–473.
   PubMed Web of Science ®Google Scholar
• SNVEKJ, GOURLAY ML, SLAWSON DC, SHAUGHNESSY AF: How to write an evidence-based clinical review article. Am. Fam. Physician (2002) 65:251–258.
   PubMedGoogle Scholar
• MALERBA M, ROMANELLI G, GRASSI V: Glucocorticoid-induced osteoporosis in asthma and respiratory diseases. Front Dorm. Res. (2002) 30:86–93.
   PubMedGoogle Scholar
• CONRON M, BEYNON HL: Churg-Strauss syndrome. Thorax (2000) 55:870–877.
   PubMed Web of Science ®Google Scholar
• GAYRAUD M, GUILLEVIN L, COHEN P et al.: Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br. Rheumatol (1997) 36:1290–1297.
   Google Scholar
• GUILLEVIN L, JARROUSSE B, LOK C et al.: Longterm-followup after treatment of polyarteriitis nodosa and Chrug-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The cooperative Study Group for Polyarteritis nodosa.j Rheumatol (1991) 18:567–574.
   Google Scholar
• LANGFORD CA: Treatment of polyarteritis nodosa, microscopic polyangiitis, and Churg- Strauss syndrome: where do we stand? Arthritic Rheum. (2001) 44:508–512.
   Google Scholar
• GAYRAUD M, GUILLEVIN L, LE TOUMELIN P et al: Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. (2001) 44:666–675.
   PubMed Web of Science ®Google Scholar
• HOFFMAN G: Treatment of Wegener's granulomatosis: time to change the standard of care? Arthritic Rheum. (1997) 40:2099–2104.
   Google Scholar
• DE GROOT K: Randomised controlled trials and new drugs. Ann. Rheum. Dis. (2003) 62:53.
   Web of Science ®Google Scholar
• BRADLEY JD, BRANDT KD, KATZ BP: Infectious complications of cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis. Arthritis Rheum. (1989) 32:45–53.
   PubMed Web of Science ®Google Scholar
• DRAKE MJ, NIXON PM, CREW JP: Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Sal (1998) 19:45–55.
   PubMed Web of Science ®Google Scholar
• APTEKAR RG, ATKINSON JP, DECKER JL, WOLFF SM, CHU EW: Bladder toxicity with chronic oral cyclophosphamide therapy in nonmalignant disease. Arthritis Rheum. (1973) 16:461–467.
   PubMed Web of Science ®Google Scholar
• JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl. Med. (2003) 349:36–44.
   PubMed Web of Science ®Google Scholar
• ••A large, randomised trial in patients withWegener's granulomatosis and microscopic polyangiitis showing that induction treatment with cyclophosphamide for 3 months, followed by maintenance treatment with azathioprine, when compared to cyclophosphamide administered for 1 year is similarly effective
   Google Scholar
• HASELBERGER MB, SCHWINGHAMMER TL: Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann. Pharmacother. (1995) 29:918–921.
   PubMed Web of Science ®Google Scholar
• SNELLER MC, HOFFMAN GS, TALAR-WILLIAMS C et al.: An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum. (1995) 38:608–613.
   PubMed Web of Science ®Google Scholar
• REINHOLD-KELLER E, FINK C, HERLYN K, GROSS WL, DE GROOT K: High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintance of remission with low-dose methotrexate. Arthritis Care Res. (2002) 47:326–332.
   Google Scholar
• BOCKENSTEDT PL, SANTINGA JT, BOLLING SF: alpha-Interferon treatment for idiopathic hypereosinophilic syndrome. Am. Hematol (1994) 45:248–251.
   PubMedGoogle Scholar
• MOHR C, SCHUTTE B, HILDEBRAND A, LUGER TA, KOLDE G: Eosinophilic pustular folliculitis: successful treatment with interferon-alpha. Dermatology (1995) 191:257–259.
   PubMedGoogle Scholar
• HUSAK R, GOERDT S, ORFANOS CE: Interferon alfa treatment of a patient with eosinophilic cellulitis and HIV infection. N. Engl. Med. (1997) 337:641–642.
   PubMedGoogle Scholar
• TATSIS E, SCHNABEL A, GROSS W: Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann. Intern. Med. (1998) 129:370–374.
   PubMed Web of Science ®Google Scholar
• ••The first report showing the efficacy ofIFN-a in CSS.
   Google Scholar
• LESENS 0, HANSMANN Y, NERSON J et al.: Severe Churg-Strauss syndrome with mediastinal lymphadenopathy treated with interferon therapy. Eur: .1. Intern. Med. (2002) 13:458.
   Google Scholar
• TERMEER CC, SIMON JC, SCHOPF E: Low-dose interferon alfa-26 for the treatment of Churg-Strauss syndrome with prominent skin involvement. Arch. Dermatol (2001) 137:136–138.
   PubMedGoogle Scholar
• REISSIG A, FORSTER M, MOCK B, SCHILDER C, KROEGEL C: [Interferon-alpha treatment of the Churg-Strauss syndrome]. Dtsch. Med. Wochenschr. (2003) 128:1475–1478.
   PubMedGoogle Scholar
• HELLMICH B, GROSS WL: [Chum-Strauss syndrome following treatment with leukotriene receptor antagonists: demasking by steroid taper or side effect?]. Dtsch. Med. Wochenschr. (2003) 128:1469.
   PubMedGoogle Scholar
• KRISHNASWAMY G, SMITH JK, SRIKANTH S et al.: Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines. Interferon Cytokine Res. (1996) 16:819–827.
   PubMed Web of Science ®Google Scholar
• ALDEBERT D, LAMKHIOUED B, DESAINT C et al.: Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood (1996) 87:2354–2360.
   PubMed Web of Science ®Google Scholar
• PORRES JC, CARRENO V, RUIZ M, MARRON JA, BARTOLOME J: Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. Hepatol (1989) 8:351–357.
   Google Scholar
• STANCEK D, FUCHSBERGER N, OLTMAN M et al.: Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2. Acta Viral. (2001) 45:287–292.
   PubMedGoogle Scholar
• GUILLEVIN L, FAIN 0, LHOTE F et al:Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteriitis nodosa and Churg-Strauss syndrome. a prospective, randomized trial in 78 patients. Arthritis Rheum. (1992) 35:208–215.
   Google Scholar
• GUILLEVIN L, LHOTE F, COHEN F et al.: Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteriitis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. (1995) 38:1638–1645.
   PubMed Web of Science ®Google Scholar
• ARBACH 0, GROSS W, GAUSE A: Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology (2002) 206:496–501.
   PubMed Web of Science ®Google Scholar
• HAMILOS DL, CHRISTENSEN J: Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Allergy Gin. Immunol (1991) 88:823–824.
   PubMed Web of Science ®Google Scholar
• LEVY Y, GEORGE J, FABBRIZZI F et al.:Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South. Med. (1999) 92:412–414.
   Google Scholar
• REID AJ, HARRISON BD, WATTS RA et al.: Churg-Strauss syndrome in a district hospital. QIM (1998) 91:219–229.
   PubMedGoogle Scholar
• MCDERMOTT EM, POWELL RJ: Cyclosporin in the treatment of Churg-Strauss syndrome. Ann. Rheum. Dis. (1998) 57:258–259.
   PubMed Web of Science ®Google Scholar
• THOMSON D, CHAMSI-PASHA H, HASLETON P: Heart transplantation for Churg-Strauss syndrome. Br. Heart (1989) 62:409–410.
   PubMedGoogle Scholar
• LECKIE MJ, TEN BRINKE A, KHAN J et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2144–2148.
   PubMed Web of Science ®Google Scholar
• O'BYRNE PM, INMAN MD, PARAMESWARAN K: The trials and tribulations of IL-5, eosinophils, and allergic asthma. I Allergy Gin. Immunol (2001) 108:503–508.
   PubMed Web of Science ®Google Scholar
• WECHSLER ME, FINN D, GUNAWARDENA D et al.: Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest (2000) 117:708–713.
   PubMed Web of Science ®Google Scholar
• WELLER PF, PLAUT M, TAGGART V, TRONTELL A: The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. Allergy Clin. Immunol (2001) 108:175–183.
   Google Scholar
• JAMALEDDINE G, DIAB K, TABBARAH Z, TAWIL A, ARAYSSI T: Leukotriene antagonists and the Churg-Strauss syndrome. Semin. Arthritic Rheum. (2002) 31:218–227.
   PubMedGoogle Scholar
• GEKELER V, ISE W, SANDERS K, ULRICH W, BECK J: The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. (1995) 208:345–352.
   PubMed Web of Science ®Google Scholar
• PRECHTL S, ROELLINGHOFF M, SCHEPER R et al.: The multidrug resistance protein 1: a functionally important activation marker for murine Thl cells. J. Immunol. (2000) 164:754–761.
   PubMed Web of Science ®Google Scholar
• ROBBIANI D, FINCH R, JAGER D et al:The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3beta ELC)-dependent mobilization of dendrtitic cells to lymph nodes. Cell (2000) 103:757–768.
   PubMed Web of Science ®Google Scholar